Biophysical characterization and crystal structure of the Feline Immunodeficiency Virus p15 matrix protein

Retrovirology

Christophe Guillon¹  Patrice Gouet¹  Magali Perez¹  Xavier Robert¹  Jennifer Serrière¹ 

[1] Laboratoire de Biocristallographie et Biologie Structurale des Cibles Thérapeutiques, IBCP-BMSSI, UMR 5086 CNRS Université de Lyon, SFR BioSciences Gerland-Lyon Sud, 7 Passage du Vercors, 69367 Lyon, Cedex 07, France

关键词: Biological dimer;    Interface;    Structure;    DLS;    Gag;    p15 matrix protein;    FIV;   

Others  :  1209113
DOI  :  10.1186/1742-4690-10-64

 received in 2012-12-21, accepted in 2013-06-13,  发布年份 2013

【 摘 要 】

Background

Feline Immunodeficiency Virus (FIV) is a viral pathogen that infects domestic cats and wild felids. During the viral replication cycle, the FIV p15 matrix protein oligomerizes to form a closed matrix that underlies the lipidic envelope of the virion. Because of its crucial role in the early and late stages of viral morphogenesis, especially in viral assembly, FIV p15 is an interesting target in the development of potential new therapeutic strategies.

Results

Our biochemical study of FIV p15 revealed that it forms a stable dimer in solution under acidic conditions and at high concentration, unlike other retroviral matrix proteins. We determined the crystal structure of full-length FIV p15 to 2 Å resolution and observed a helical organization of the protein, typical for retroviral matrix proteins. A hydrophobic pocket that could accommodate a myristoyl group was identified, and the C-terminal end of FIV p15, which is mainly unstructured, was visible in electron density maps. As FIV p15 crystallizes in acidic conditions but with one monomer in the asymmetric unit, we searched for the presence of a biological dimer in the crystal. No biological assembly was detected by the PISA server, but the three most buried crystallographic interfaces have interesting features: the first one displays a highly conserved tryptophan acting as a binding platform, the second one is located along a 2-fold symmetry axis and the third one resembles the dimeric interface of EIAV p15. Because the C-terminal end of p15 is involved in two of these three interfaces, we investigated the structure and assembly of a C-terminal-truncated form of p15 lacking 14 residues. The truncated FIV p15 dimerizes in solution at a lower concentration and crystallizes with two molecules in the asymmetric unit. The EIAV-like dimeric interface is the only one to be retained in the new crystal form.

Conclusion

The dimeric form of FIV p15 in solution and its extended C-terminal end are characteristic among lentiviral matrix proteins. Crystallographic interfaces revealed several interactions that might be involved in FIV replication. Further studies are needed to better understand their biological relevance in the function of FIV Gag during viral replication.

【 授权许可】

   
2013 Serrière et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Troyer JL, Pecon-Slattery J, Roelke ME, Johnson W, VandeWoude S, Vazquez-Salat N, Brown M, Frank L, Woodroffe R, Winterbach C, et al.: Seroprevalence and genomic divergence of circulating strains of feline immunodeficiency virus among Felidae and Hyaenidae species. J Virol 2005, 79:8282-8294.
• [2]Winkler IG, Lochelt M, Flower RL: Epidemiology of feline foamy virus and feline immunodeficiency virus infections in domestic and feral cats: a seroepidemiological study. J Clin Microbiol 1999, 37:2848-2851.
• [3]Burkhard MJ, Dean GA: Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 2003, 1:15-29.
• [4]Elder JH, Lin YC, Fink E, Grant CK: Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res 2010, 8:73-80.
• [5]Prasad GS, Stura EA, McRee DE, Laco GS, Hasselkus-Light CS, Elder JH, Stout CD: Crystal structure of dUTP pyrophosphatase from feline immunodeficiency virus. Protein Sci 1996, 5:2429-2437.
• [6]Laco GS, Schalk-Hihi C, Lubkowski J, Morris G, Zdanov A, Olson A, Elder JH, Wlodawer A, Gutschina A: Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 1997, 36:10696-10708.
• [7]Wlodawer A, Gutschina A, Reshetnikova L, Lubkowski J, Zdanov A, Hui KY, Angleton EL, Farmerie WG, Goodenow MM, Bhatt D: Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol 1995, 2:480-488.
• [8]Freed EO: HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 251:1-15.
• [9]Freed EO, Martin MA: The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995, 270:23883-23886.
• [10]Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996, 70:341-351.
• [11]Dalton AK, Ako-Adjei D, Murray PS, Murray D, Vogt VM: Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain. J Virol 2007, 81:6434-6445.
• [12]Freed EO, Orenstein JM, Buckler-White AJ, Martin MA: Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994, 68:5311-5320.
• [13]Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI: Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci USA 1996, 93:3099-3104.
• [14]Yuan X, Yu X, Lee TH, Essex M: Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 1993, 67:6387-6394.
• [15]Zhou W, Parent LJ, Wills JW, Resh MD: Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 1994, 68:2556-2569.
• [16]Nermut MV, Hockley DJ, Jowett JB, Jones IM, Garreau M, Thomas D: Fullerene-like organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 1994, 198:288-296.
• [17]Henderson LE, Sowder RC, Smythers GW, Oroszlan S: Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins. J Virol 1987, 61:1116-1124.
• [18]Schultz AM, Henderson LE, Oroszlan S: Fatty acylation of proteins. Annu Rev Cell Biol 1988, 4:611-647.
• [19]Elder JH, Schnolzer M, Hasselkus-Light CS, Henson M, Lerner DA, Phillips TR, Wagaman PC, Kent SB: Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J Virol 1993, 67:1869-1876.
• [20]Coffin JM: Retroviridae: the viruses and their replication. 3rd ed edn. Philadelphia, Pa: Lippincott-Raven Publishers; 1996.
• [21]Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, Summers MF: Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad Sci USA 2004, 101:517-522.
• [22]Zhou W, Resh MD: Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol 1996, 70:8540-8548.
• [23]Hermida-Matsumoto L, Resh MD: Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA. J Virol 1999, 73:1902-1908.
• [24]Paillart JC, Gottlinger HG: Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting. J Virol 1999, 73:2604-2612.
• [25]Resh MD: A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc Natl Acad Sci USA 2004, 101:417-418.
• [26]Alfadhli A, Huseby D, Kapit E, Colman D, Barklis E: Human immunodeficiency virus type 1 matrix protein assembles on membranes as a hexamer. J Virol 2007, 81:1472-1478.
• [27]Forster MJ, Mulloy B, Nermut MV: Molecular modelling study of HIV p17gag (MA) protein shell utilising data from electron microscopy and X-ray crystallography. J Mol Biol 2000, 298:841-857.
• [28]Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF: Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci USA 2006, 103:11364-11369.
• [29]Tang C, Ndassa Y, Summers MF: Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat Struct Biol 2002, 9:537-543.
• [30]Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI: Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol 1994, 244:198-223.
• [31]Hatanaka H, Iourin O, Rao Z, Fry E, Kingsman A, Stuart DI: Structure of equine infectious anemia virus matrix protein. J Virol 2002, 76:1876-1883.
• [32]Rao Z, Belyaev AS, Fry E, Roy P, Jones IM, Stuart DI: Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 1995, 378:743-747.
• [33]Riffel N, Harlos K, Iourin O, Rao Z, Kingsman A, Stuart D, Fry E: Atomic resolution structure of Moloney murine leukemia virus matrix protein and its relationship to other retroviral matrix proteins. Structure 2002, 10:1627-1636.
• [34]Wilkins DK, Grimshaw SB, Receveur V, Dobson CM, Jones JA, Smith LJ: Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry 1999, 38:16424-16431.
• [35]Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A: Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J Virol 2008, 82:2405-2417.
• [36]Grimes J, Basak AK, Roy P, Stuart D: The crystal structure of bluetongue virus VP7. Nature 1995, 373:167-170.
• [37]Krissinel E, Henrick K: Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007, 372:774-797.
• [38]Fledderman EL, Fujii K, Ghanam RH, Waki K, Prevelige PE, Freed EO, Saad JS: Myristate exposure in the human immunodeficiency virus type 1 matrix protein is modulated by pH. Biochemistry 2011, 49:9551-9562.
• [39]Schuldiner S, Rozengurt E: Na+/H + antiport in Swiss 3T3 cells: mitogenic stimulation leads to cytoplasmic alkalinization. Proc Natl Acad Sci USA 1982, 79:7778-7782.
• [40]Moolenaar WH, Tsien RY, van der Saag PT, de Laat SW: Na+/H + exchange and cytoplasmic pH in the action of growth factors in human fibroblasts. Nature 1983, 304:645-648.
• [41]Gottlieb RA, Giesing HA, Zhu JY, Engler RL, Babior BM: Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA 1995, 92:5965-5968.
• [42]Makutonina A, Voss TG, Plymale DR, Fermin CD, Norris CH, Vigh S, Garry RF: Human immunodeficiency virus infection of T-lymphoblastoid cells reduces intracellular pH. J Virol 1996, 70:7049-7055.
• [43]Perez-Caballero D, Hatziioannou T, Martin-Serrano J, Bieniasz PD: Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. J Virol 2004, 78:9560-9563.
• [44]Saad JS, Ablan SD, Ghanam RH, Kim A, Andrews K, Nagashima K, Soheilian F, Freed EO, Summers MF: Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol 2008, 382:434-447.
• [45]Kuiken CL, Foley B, Leitner T, Hahn BH, Apetrei C, Mizrachi I, Mullins JI, Rambaut A, Marx PA, Wolinksy S, Korber B (Eds): HIV Sequence Compendium 2010. Los Alamos: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos; 2010.
• [46]Matthews S, Barlow P, Clark N, Kingsman S, Kingsman A, Campbell I: Refined solution structure of p17, the HIV matrix protein. Biochem Soc Trans 1995, 23:725-729.
• [47]Massiah MA, Worthylake D, Christensen AM, Sundquist WI, Hill CP, Summers MF: Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly. Protein Sci 1996, 5:2391-2398.
• [48]Fuller SD, Wilk T, Gowen BE, Krausslich HG, Vogt VM: Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle. Curr Biol 1997, 7:729-738.
• [49]Wilk T, Gross I, Gowen BE, Rutten T, de Haas F, Welker R, Krausslich HG, Boulanger P, Fuller SD: Organization of immature human immunodeficiency virus type 1. J Virol 2001, 75:759-771.
• [50]Chazal N, Gay B, Carriere C, Tournier J, Boulanger P: Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol 1995, 69:365-375.
• [51]Yu X, Yu QC, Lee TH, Essex M: The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol 1992, 66:5667-5670.
• [52]Lee YM, Tang XB, Cimakasky LM, Hildreth JE, Yu XF: Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes. J Virol 1997, 71:1443-1452.
• [53]Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP: Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996, 87:1285-1294.
• [54]Yoo S, Myszka DG, Yeh C, McMurray M, Hill CP, Sundquist WI: Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol 1997, 269:780-795.
• [55]Gallay P, Swingler S, Song J, Bushman F, Trono D: HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 1995, 83:569-576.
• [56]Serrière J, Dugua J-M, Bossus M, Verrier B, Haser R, Gouet P, Guillon C: Fab'-induced folding of antigenic N-terminal peptides from intrinsically unstructured HIV-1 Tat protein revealed by X-ray crystallography. J Mol Biol 2011, 405:33-42.
• [57]Serrière J, Fenel D, Schoehn G, Gouet P, Guillon C: Biophysical characterization of the Feline Immunodeficiency Virus p24 Capsid protein conformation and in vitro capsid assembly. PLoS One 2013, 8:e56424.
• [58]Kabsch W: Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 1993, 26:795-800.
• [59]Keegan RM, Winn MD: Automated search-model discovery and preparation for structure solution by molecular replacement. Acta Crystallogr D Biol Crystallogr 2007, 63:447-457.
• [60]Morris RJ, Perrakis A, Lamzin VS: ARP/wARP and automatic interpretation of protein electron density maps. Methods Enzymol 2003, 374:229-244.
• [61]Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al.: PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66:213-221.
• [62]Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60:2126-2132.
• [63]Nicholls A, Sharp KA, Honig B: Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991, 11:281-296.
• [64]Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Computational Chemistry 1998, 19:1639-1662.
• [65]Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ: Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Computational Chemistry 2009, 30:2785-2791.
• [66]Gouet P, Courcelle E: ENDscript: a workflow to display sequence and structure information. Bioinformatics 2002, 18:767-768.
• [67]ESPript. http://espript.ibcp.fr webcite
• [68]Protein Data Bank. http://www.rcsb.org webcite